Submit Deal

Announced

17 Apr 2025

Completed

17 Apr 2025

Section 32 led a $120m Series B round in BigHat Biosciences.

Synopsis

Section 32, a venture capital fund, led a $120m Series B round in BigHat Biosciences, a biotechnology company, with participation from Amgen Ventures, Bristol Myers Squibb, Quadrille Capital, Gaingels, GRIDS Capital, Andreessen Horowitz, 8VC, and AME Cloud Ventures.

Principals

target

Bighat Biosciences

bidder

Section 32 (s32)

Show Details & Financials

Did you work on this deal?

Claim Deal

Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.

Claim Deal

Market Context

Sort

Seller Team (1)

mark depristo

Founder and CEO at BIGHAT BIOSCIENCES

Manager

target

Deals

£ 167 M

Total Value

Bidder Team (10)

andy harrison

Managing Partner at SECTION 32 (S32)

Manager

bidder

Deals

£ 493 M

Total Value

dror berman

CEO at INNOVATION ENDEAVORS

Investor

bidder

Deal

£ 90 M

Total Value

joe lonsdale

‎Founder and Managing Partner at 8VC (EIGHT PARTNERS LLC)

Investor

bidder

Deals

£ 250 M

Total Value

philip tagari

Vice President at AMGEN VENTURES

Investor

bidder

Deals

£ 165 M

Total Value

ben horowitz

Co-Founder and General Partner at ANDREESSEN HOROWITZ LLC (A16Z)

Investor

bidder

Deals

£ 128 M

Total Value

guy perelmuter

C-Founder and CEO at GRIDS CAPITAL

Manager

bidder

Deals

£ 152 M

Total Value

giovanni caforio

Chairman and CEO at BRISTOL MYERS SQUIBB COMPANY

Manager

bidder

Deals

£ 107.32 B

Total Value

jennifer jeronimo

CEO and General Partner at GAINGELS

Investor

bidder

Deals

£ 817 M

Total Value

jerome chevalier

Founding Partner at QUADRILLE CAPITAL

Investor

bidder

Deals

£ 290 M

Total Value

jerry yang

Founding Partner at AME CLOUD VENTURES

Investor

bidder

Deals

£ 697 M

Total Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy